Semax

Semax is a synthetic heptapeptide derived from the adrenocorticotropic hormone (ACTH), specifically the ACTH(4-10) analog. This compound has garnered interest for its potential effects on cognitive enhancement, neuroprotection, and mood support, with various studies examining its mechanisms of action and benefits in clinical settings.

II. What is this compound?

Semax is a heptapeptide that consists of seven amino acids with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, designed as an analog of the adrenocorticotropic hormone (ACTH). It was developed in Russia during the 1980s as a potential therapeutic agent to enhance cognitive functions and provide neuroprotection following stress and hypoxia. Semax is synthetically derived from the N-terminal portion of the ACTH peptide, specifically modified to include a methionine group, which is vital for its bioactivity.

The peptide exhibits a short half-life, typically measured in minutes. To overcome this limitation, Semax is frequently administered via intranasal and subcutaneous routes. The nasal spray formulation has been particularly noted for its capacity to extend the local bioavailability of Semax, allowing it to effectively target neural tissues while minimizing systemic exposure.

III. How it works

• BDNF expression enhancement in hippocampus and cortex
  PMID 21833148PMID 25313017
• TrkB receptor activation promoting neuroplasticity
  PMID 21833148
• Modulation of serotonin and dopamine neurotransmitter systems
  PMID 25313017

IV. Research Findings

• cognitive-enhancement clinical
  PMID 21833148PMID 25313017
• neuroprotection preclinical
  PMID 21833148
• mood-support preclinical
  PMID 25313017

V. Dosage Context Explained

• Administration Routes

  intranasal

  Range

  0.1–1 mg/day

  clinical studies for cognitive impairment and optic nerve atrophy

  PMID 25313017

VI. Side Effects: Research Context

• nasal irritation (with spray formulation)
• transient headache
• mild anxiety at higher doses (anecdotal)